Table 2 Treatments for complications of retinal vein occlusion administered during the study period
Treatment, n (%) | Monotherapy n = 84 | Combination therapy n = 205 |
|---|---|---|
DEX implant | 84 (100) | 205 (100) |
Any other treatment | 0 (0) | 205 (100) |
Intravitreal injection | ||
Anti-VEGF | 186 (90.7) | |
Bevacizumab | 127 (62.0) | |
Ranibizumab | 94 (45.9) | |
Triamcinolone | 9 (4.4) | |
Laser | 72 (35.1) | |
PRP | 27 (13.2) | |
Focal | 54 (26.3) |